The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    526

  • View Count
    4560

Example Insights

Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Context Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Key-drivers Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-List-of-approved-drugs Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Type-of-molecule
Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Technology-developers ubcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Pipeline 	Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Partnerships-and-collaborations Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-key-parameters
Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Competitveness-analysis Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Market-forecast Subcutaneous-Biologics-Technologies- -and-Drug-Delivery Systems-Futuer-forecast  

 

Overview

Biologics represent one of the fastest growing classes of therapeutic molecules in modern healthcare. As per an article published in January 2020, the annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Considering the necessity to bypass gastric metabolism, biologics are mostly designed for administration via parenteral routes. In fact, majority of such therapies are formulated for intravenous delivery and are usually administered in a clinical setting (hospitals / infusion centers). However, this scenario is cost intensive and is known to be associated with medication adherence related concerns. In this context, the subcutaneous route of drug delivery offers a number of benefits, including self-medication and life cycle management options. Although the pharmacokinetic profiles of intravenous and subcutaneous formulations are different, studies have demonstrated that the latter formulations are preferred by end users (patients and healthcare providers), offering substantial cost saving opportunities. 

Presently, the subcutaneous delivery option is being investigated for a number of clinical candidates across different phases of development. Moreover, several approved therapeutic products, which are currently available in intravenous dosage forms, are also being reformulated and evaluated for subcutaneous administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been shown to result in highly viscous formulations when reformulated for subcutaneous delivery. In order to address this particular challenge, many companies have developed / are developing a number of novel technology platforms to facilitate the delivery of viscous drug formulations. Similar innovations are gradually facilitating a shift to subcutaneous delivery, primarily driven by the demand for self-administrable therapeutics. In fact, there are several self-medication solutions, equipped with a variety of user-friendly features, available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed high adoption, enabled substantial reductions in healthcare expenses (incurred by patients), and improved therapy adherence. In this regard, the rising incidence of chronic clinical conditions (which are characterized by the need for frequent medication) and the ongoing efforts of therapy / device developers engaged in this field, are anticipated to drive the growth of the subcutaneous biologics market in the coming years.

Scope of the Report

The ‘Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030’ report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route, along with information on approval year, phase of development, type of pharmacological molecule, target  therapeutic area, dosing frequency, available dosage forms and key players. 
  • A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
  • An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s). 
  • An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. Also, the study includes a detailed benchmark analysis of the technology developers based in North America and Europe, highlighting the primary advantage(s) offered by their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration.
  • Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.
  • An analysis of collaborations  and partnership agreements inked by the subcutaneous formulation technology developers since 2011; it includes details of deals that were / are focused on subcutaneous formulation technologies, which were analyzed on the basis of year of agreement, type of agreement, and upfront and milestone payments.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: Stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force). 
  • Autoinjectors: Usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual). 
  • Pen injectors: Usability (disposable and reusable), volume / storage capacity (in mL), and type of  dose (fixed dose and variable dose).
  • Needle-free injection systems: Stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others).
  • Drug reconstitution systems: Usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others).
  • Prefilled syringes: Barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL).
  • Implants: Stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. 
  • A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market. 

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential of the subcutaneous biologics, technologies and drug delivery systems market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] phase of development (approved, preregistration & phase III and phase II & phase II/III)), [B] type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), [C] target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: 

  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals)
  • David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices)
  • Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • David Heuzé (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Recent Developments

  • European Commission Grants Marketing Authorisation for DARZALEX (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications (Source)
  • European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease (Source)

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the subcutaneous biologics, technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction to the various types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecule structure, immunogenicity and stability. The chapter also highlights different types of biologically derived products that are currently being developed by various stakeholders in this industry. It further discusses the challenges associated with the parenteral route of drug delivery, specifically, those related to the traditional intravenous (infusion) route. Further, the chapter features a discussion on the different routes of administration, specifically focusing on the subcutaneous route, highlighting its advantages and associated limitations. 

Chapter 4 includes information on over 450 subcutaneous biologic drug candidates that are currently approved / being developed. It features a comprehensive analysis of marketed  and clinical-stage biologics based on the approval year, phase of development type of pharmacological molecule, target  therapeutic area, dosing frequency, available dosage forms and key players. 

Chapter 5 is a collection of case studies on the leading subcutaneous biologics, in terms of the annual global sales. Each case study includes drug / therapy specifications, their respective mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).

Chapter 6 provides a list of subcutaneous formulation technologies that are currently available / being developed by various firms in this domain. The chapter highlights key features of each technology and provides information on their developers. It also features an analysis based on the type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s). 

Chapter 7 features a three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. It also includes a benchmark analysis of technology developers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration

Chapter 8 includes elaborate profiles of key technology developers, featuring overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the subcutaneous formulation technologies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2011. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants. It includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable injectors, by stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force), [B] autoinjectors, by usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual), [C] pen-injectors, by usability (disposable and reusable), volume / storage capacity (in mL), and type of  dose (fixed dose and variable dose), [D] needle-free injection systems, by stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others), [E] drug reconstitution systems, by usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others), [F] prefilled syringes, by barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL),  and [G] implants, by stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. As large volume wearable injectors, pre-filled syringes, needle-free injectors and autoinjectors represent the most novel and advanced types of devices, we have also provided a comprehensive product competitiveness analysis of these products taking into consideration the supplier power (based on size of employee base) and product specifications.

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market. 

Chapter 12 presents an informed estimate of the current and future opportunity in the subcutaneous biologics, technologies and drug delivery systems  market, highlighting the likely growth of the market till the year 2030. It also includes future sales projections of various subcutaneous biologic drug candidates that are currently being evaluated by different players. The chapter presents a detailed market segmentation on the basis of phase of development (approved, preregistration & phase III and phase II and phase II/III), type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors, drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics.

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuzé (Communication Leader, MedinCell).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologically Derived Therapeutics
3.3.1. Types of Products
3.3.2. Routes of Administration and Formulations
3.3.3. Subcutaneous Formulations
3.3.3.1. Approaches in Subcutaneous Delivery of Biologics
3.3.3.1.1. Reformulation
3.3.3.1.2. Differing Potencies
3.3.3.1.3. Novel Technologies

3.3.3.2. Method of Subcutaneous Administration
3.3.3.3. Advantages of Subcutaneous Administration
3.3.3.4. Limitations of Subcutaneous Administration

3.4. Regulatory Considerations
3.4.1. Medical Devices
3.4.2. Drug Device Combination Products

3.5. Future Perspectives
 
4. SUBCUTANEOUS BIOLOGICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Subcutaneous Administration of Biologics
4.3. Subcutaneous Biologics: List of Approved Drugs
4.3.1. Analysis by Approval Year
4.3.2. Analysis by Type of Pharmacological Molecule
4.3.3. Analysis by Target Therapeutic Area
4.3.4. Analysis by Type of Formulation 
4.3.5. Analysis by Dosing Frequency
4.3.6. Analysis by Dosage Form
4.3.7. Key Players: Analysis by Number of Drugs Approved

4.4. Subcutaneous Biologics: List of Clinical-Stage Drug Candidates
4.4.1. Analysis by Phase of Development
4.4.2. Analysis by Type of Pharmacological Molecule
4.4.3. Analysis by Target Therapeutic Area
4.4.4. Analysis by Dosing Frequency
4.4.5. Key Players: Analysis by Number of Drug Candidates in Trials

5. SUNCUTANEOUS BIOLOGICS: CASE STUDIES OF LEADING PRODUCTS
5.1. Chapter Overview
5.2. Subcutaneous Biologics: Leading Drugs by Annual Sales

5.3. Case Studies
5.3.1. HUMIRA® (AbbVie, Eisai)
5.3.1.1. Overview
5. 3.1.2. Development History
5. 3.1.3. Target Indications and Dosage Forms
5. 3.1.4. Historical Sales

5.3.2. Enbrel® (Amgen, Pfizer, Takeda Pharmaceutical)
5.3.2.1. Overview
5. 3.2.2. Development History
5. 3.2.3. Target Indications and Dosage Forms
5. 3.2.4. Historical Sales

5.3.3. RITUXAN® / MabThera® (Biogen, Roche, Chugai Pharmaceutical)
5.3.3.1. Overview
5. 3.3.2. Development History
5. 3.3.3. Target Indications and Dosage Forms
5. 3.3.4. Historical Sales
5. 3.3.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.3.6. Advantages of Subcutaneous RITUXAN® / MabThera® Over Intravenous RITUXAN® / MabThera®

5.3.4. Herceptin® (Roche, Chugai Pharmaceutical)
5.3.4.1. Overview
5. 3.4.2. Development History
5. 3.4.3. Target Indications and Dosage Forms
5. 3.4.4. Historical Sales
5. 3.4.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.4.6. Advantages of Subcutaneous Herceptin® Over Intravenous Herceptin®
5. 3.4.7. Herceptin® - Large Volume Wearable Injector Combination Product

5.3.5. Neulasta® (Amgen, Kyowa Hakko Kirin)
5.3.5.1. Overview
5.3.5.2. Development History
5.3.5.3. Target Indications and Dosage Forms
5.3.5.4. Historical Sales

6. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Subcutaneous Formulation Technologies: List of Technology Developers
6.2.1. Analysis by Year of Establishment of Developers
6.2.2. Analysis by Size of Developers
6.2.3. Analysis by Geographical Location of Developers
6.2.4. Analysis by Type of Pharmacological Molecule
6.2.5. Analysis by Route of Administration
6.2.6. Analysis by Advantage(s) Offered 

7. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Subcutaneous Formulation Technology Developers: Competitive Landscape
7.2.1. Scope and Methodology
7.2.2. Four-Dimensional Bubble Analysis based on Supplier Power, Pipeline Strength, Primary Advantage(s) and Geographical Location

7.3. Subcutaneous Formulation Technology Developers: Benchmark Analysis
7.3.1. Scope and Methodology
7.3.2. North America
7.3.3. Europe

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES
8.1. Chapter Overview
8.2. Adocia
8.2.1. Company Overview
8.2.2. Technology Overview
8.2.2.1. BioChaperone® Technology
8.2.3. Product Portfolio
8.2.4. Financial Performance
8.2.5. Recent Developments and Future Outlook

8.3. Ajinomoto Bio-Pharma Services
8.3.1. Company Overview
8.3.2. Technology Overview
8.3.2.1. Crystalomics® Formulation Technology
8.3.3. Product Portfolio
8.3.4. Financial Performance
8.3.5. Recent Developments and Future Outlook

8.4. Arecor
8.4.1. Company Overview
8.4.2. Technology Overview
8.4.2.1. Arestat™ Technology
8.4.3. Product Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Alteogen
8.5.1. Company Overview
8.5.2. Technology Overview
8.5.2.1. Hybrozyme Technology
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. Ascendis Pharma
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.2.1. TransCon Technology
8.6.3. Product Portfolio
8.6.4. Financial Performance
8.6.5. Recent Developments and Future Outlook

8.7. Avadel Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Overview
8.7.2.1. Medusa™ Technology
8.7.3. Product Portfolio
8.7.4. Financial Performance
8.7.5. Recent Developments and Future Outlook

8.8. Camurus
8.8.1. Company Overview
8.8.2. Technology Overview
8.8.2.1. FluidCrystal® Injection Depot Technology
8.8.3. Product Portfolio
8.8.4. Financial Performance
8.8.5. Recent Developments and Future Outlook

8.9. Creative BioMart
8.9.1. Company Overview
8.9.2. Technology Overview
8.9.2.1. High Concentration Formulation Technology

8.10. Creative Biolabs
8.10.1. Company Overview
8.10.2. Technology Overview
8.10.2.1. Long-Acting Injectable Technology

8.11. DURECT
8.11.1. Company Overview
8.11.2. Technology Overview
8.11.2.1. SABER® Platform
8.11.2.2. CLOUD™ PLATFORM
8.11.3. Product Portfolio
8.11.4. Financial Performance
8.11.5. Recent Developments and Future Outlook

8.12. Eagle Pharmaceuticals
8.12.1. Company Overview
8.12.2. Technology Overview
8.12.2.1. Unnamed Technology
8.12.3. Financial Performance

8.13. Halozyme Therapeutics
8.13.1. Company Overview
8.13.2. Technology Overview
8.13.2.1. ENHANZE® Technology
8.13.3. Product Portfolio
8.13.4. Financial Performance
8.13.5. Recent Developments and Future Outlook

8.14. MedinCell
8.14.1. Company Overview
8.14.2. Technology Overview
8.14.2.1. BEPO® Technology
8.14.3. Product Portfolio
8.14.4. Recent Developments and Future Outlook

8.15. Xeris Pharmaceuticals
8.15.1. Company Overview
8.15.2. Technology Overview
8.15.2.1. XeriJect™ Technology
8.15.2.2. XeriSol™ Technology
8.15.3. Product Portfolio
8.15.4 Financial Performance
8.15.5. Recent Developments and Future Outlook

8.16. Serina Therapeutics
8.16.1. Company Overview
8.16.2. Technology Overview
8.16.2.1. POZ™ Drug Delivery Technology
8.16.3. Product Portfolio
8.16.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Subcutaneous Formulation Technologies: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.5. Intercontinental and Intracontinental Agreements

10. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Different Types of Subcutaneous Drug Delivery Systems
10.3. Subcutaneous Drug Delivery Systems: Overall Market Landscape
10.3.1. Large Volume Wearable Injectors
10.3.1.1. Overview
10.3.1.2. Current Market Landscape of Devices for Non-insulin Biologics
10.3.1.2.1. Analysis by Stage of Development
10.3.1.2.2. Analysis by Type of Device
10.3.1.2.3. Analysis by Type of Dose Administered
10.3.1.2.4. Analysis by Volume / Storage Capacity
10.3.1.2.5. Analysis by Usability
10.3.1.2.6. Analysis by Mode of Injection
10.3.1.2.7. Analysis by Mechanism of Action
10.3.1.2.8. Most Active Players: Analysis by Number of Devices

10.3.1.3. Current Market Landscape of Devices for Insulin
10.3.1.3.1. Analysis by Stage of Development
10.3.1.3.2. Analysis by Type of Device
10.3.1.3.3. Analysis by Volume / Storage Capacity
10.3.1.3.4. Analysis by Usability
10.3.1.3.5. Analysis by Availability of Integrated CGM / BGM System
10.3.1.3.6. Most Active Players: Analysis by Number of Devices

10.3.1.4. Drug Device Combination Products
10.3.1.5. Product Competitiveness Analysis
10.3.1.5.1. Large Volume Wearable Injectors for Non-Insulin Drugs
10.3.1.5.2. Large Volume Wearable Injectors for Insulin

10.3.2. Autoinjectors
10.3.2.1. Overview
10.3.2.2. Current Market Landscape
10.3.2.2.1. Analysis by Usability
10.3.2.2.2. Analysis by Type of Primary Container
10.3.2.2.3. Analysis by Volume / Storage Capacity
10.3.2.2.4. Analysis by Type of Dose
10.3.2.2.5. Analysis by Actuation Mechanism
10.3.2.2.6. Most Active Players: Analysis by Number of Devices
10.3.2.3. Product Competitiveness Analysis
10.3.2.4. Drug Device Combination Products

10.3.3. Pen Injectors
10.3.3.1. Overview
10.3.3.2. Current Market Landscape
10.3.3.2.1. Analysis by Usability
10.3.3.2.2. Analysis by Volume / Storage Capacity
10.3.3.2.3. Analysis by Type of Dose
10.3.3.2.4. Most Active Players: Analysis by Number of Devices
10.3.3.3. Drug Device Combination Products

10.3.4. Needle-Free Injection Systems
10.3.4.1. Overview
10.3.4.2. Current Market Landscape
10.3.4.2.1. Analysis by Stage of Development
10.3.4.2.2. Analysis by Usability
10.3.4.2.3. Analysis by Disease Area
10.3.4.2.4. Analysis by Actuation Mechanism
10.3.4.2.5. Most Active Players: Analysis by Number of Devices
10.3.4.3. Product Competitiveness Analysis
10.3.4.3.1. Spring-Based Needle-Free Injection Systems
10.3.4.3.2. Gas-Powered Needle-Free Injection Systems

10.3.5. Novel Drug Reconstitution Delivery Systems
10.3.5.1. Overview
10.3.5.2. Current Market Landscape
10.3.5.2.1. Analysis by Usability
10.3.5.2.2. Analysis by Type of Device
10.3.5.2.3. Analysis by Dosage Type
10.3.5.2.4. Analysis by Type of Drug Container
10.3.5.2.5. Most Active Players: Analysis by Number of Devices
10.3.6. Prefilled Syringes
10.3.6.1. Overview
10.3.6.2. Current Market Landscape
10.3.6.2.1. Analysis by Barrel Fabrication Material
10.3.6.2.2. Analysis by Number of Barrel Chambers
10.3.6.2.3. Analysis by Type of Needle System
10.3.6.2.4. Analysis by Volume / Storage Capacity
10.3.6.3.5. Most Active Players: Analysis by Number of Devices
10.3.6.3. Product Competitiveness Analysis
10.3.6.3.1. Glass Barrel Syringes
10.3.6.3.2. Plastic Barrel Syringes
10.3.6.4. Drug Device Combination Products

10.3.7. Implants
10.3.7.1. Overview
10.3.7.2. Current Market Landscape
10.3.7.2.1. Analysis by Stage of Development
10.3.7.2.2. Analysis by Target Therapeutic Area
10.3.7.2.3. Analysis by Implant Material
10.3.7.2.4. Analysis by Treatment Duration
10.3.7.2.5. Analysis by Type of Delivery System
10.3.7.2.6. Most Active Players: Analysis by Number of Devices
103.3.7.3. Subcutaneous Implants Eluting Small Molecules

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Comparison of SWOT Factors
11.2.1. Strengths
11.2.2. Weaknesses
11.2.3. Opportunities
11.2.4. Threats

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Subcutaneous Biologics Market
12.2.1. Forecast Methodology and Key Assumptions
12.2.2. Overall Subcutaneous Biologics Market, 2020-2030
12.2.2.1. Subcutaneous Biologics Market, 2020-2030:Distribution by Phase of Development
12.2.2.2. Subcutaneous Biologics Market, 2020-2030:Distribution by Type of Pharmacological Molecule
12.2.2.3. Subcutaneous Biologics Market, 2020-2030:Distribution by Target Therapeutic Area

12.3. Subcutaneous Drug Delivery Systems Market
12.3.1. Device Type 1: Large Volume Wearable Injectors
12.3.1.1. Forecast Methodology and Key Assumptions
12.3.1.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030
12.3.1.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030
12.3.1.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030
12.3.1.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030

12.3.1.3. Global Large Volume Wearable Injectors Market for Insulin , 2020-2030
12.3.1.3.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030
12.3.1.3.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030

12.3.2. Device Type 2: Autoinjectors
12.3.2.1. Forecast Methodology and Key Assumptions
12.3.2.2. Global Autoinjectors Market, 2020-2030
12.3.2.2.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030
12.3.2.2.2. Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030

12.3.3. Device Type 3: Prefilled Syringes
12.3.3.1. Forecast Methodology and Key Assumptions
12.3.3.2. Global Prefilled Syringes Market, 2020-2030
12.3.3.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
12.3.3.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
12.3.3.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
12.3.3.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030

12.3.4. Device Type 4: Needle-Free Injection Systems
12.3.4.1. Forecast Methodology and Key Assumptions
12.3.4.2. Global Needle-Free Injection Systems Market, 2020-2030
12.3.4.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
12.3.4.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
12.3.4.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030

12.3.5. Device Type 5: Novel Drug Reconstitution Systems
12.3.5.1. Forecast Methodology and Key Assumptions
12.3.5.2. Global Novel Drug Reconstitution Systems Market, 2020-2030

12.4. Subcutaneous Formulation Technologies Market
12.4.1. Forecast Methodology and Key Assumptions
12.4.2. Subcutaneous Formulation Technologies Market, 2020-2030
12.4.2.1. Subcutaneous Formulation Technologies Market by Upfront Payments, 2020-2030
12.4.2.2. Subcutaneous Formulation Technologies Market by Milestone Payments, 2020-2030

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview

14.2. Lindy Biosciences
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder

14.3. Oval Medical Technologies
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder

14.4. Xeris Pharmaceuticals
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Sr. Scientist Formulation)

14.5. DALI Medical Devices
14.5.1. Company Snapshot
14.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder

14.6. Excelse Bio
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder

14.7. i-novion
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder

14.8. Enable Injections
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer

14.9. Immunovaccine Technologies
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Frederic Ors, Chief Executive Officer

14.10. Portal Instruments
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer

14.11. Elcam Medical
14.11.1. Company Snapshot
14.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist

14.12. West Pharmaceutical Services
14.12.1. Company Snapshot
14.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics

14.13. MedinCell
14.13.1. Company Snapshot
14.13.2. Interview Transcript: David Heuzé, Communication Leader

15. APPENDIX 1:  TABULATED DATA 

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION 

List Of Figures

Figure 3.1 Types of Biologically Derived Therapeutic Molecules
Figure 3.2 Intravenous to Subcutaneous Formulations: Key Considerations
Figure 3.3 Intravenous to Subcutaneous Formulations: Development Process
Figure 3.4 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
Figure 3.5 Large Volume Subcutaneous Drug Delivery Devices
Figure 3.6 Key Steps in Subcutaneous Drug Delivery
Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Figure 4.2 Approved Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
Figure 4.3 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
Figure 4.4 Approved Subcutaneous Biologics: Distribution by Formulation
Figure 4.5 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 4.6 Approved Subcutaneous Biologics: Distribution by Dosage Form
Figure 4.7 Key Players: Distribution by Number of Drugs Approved
Figure 4.8 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Figure 4.9 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
Figure 4.10 Clinical-Stage Subcutaneous Biologics: Distribution by Target Therapeutic Area
Figure 4.11 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 4.12 Key Players: Distribution by Number of Clinical-Stage Subcutaneous Biologics
Figure 5.1 Subcutaneous Biologics: Leading Drugs by Annual Sales, 2019 (USD Billion)
Figure 5.2 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 5.3 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 5.4 HUMIRA®: Annual Sales, 2003-Q1 2020 (USD Billion)
Figure 5.5 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 5.6 Enbrel®: Annual Sales in the US and Canada, 2002-Q1 2020 (USD Billion)
Figure 5.7 Enbrel®: Annual Sales Outside US and Canada, 2010-Q1 2020 (USD Billion)
Figure 5.8 RITUXAN® / MabThera®: Approval Timeline (US, EU and Japan)
Figure 5.9 RITUXAN® / MabThera®: Annual Sales, 1999-Q1 2020 (CHF Billion)
Figure 5.10 Herceptin®: Annual Sales, 1999-Q1 2020 (CHF Billion)
Figure 5.11 Neulasta®: Annual Sales, 2005-2019 (USD Billion)
Figure 6.1 High Concentration Biologic Formulations: Advantages
Figure 6.2 High Concentration Biologic Formulations: Associated Challenges
Figure 6.3 Subcutaneous Formulation Technologies: Distribution by Year of Establishment of Developers
Figure 6.4 Subcutaneous Formulation Technologies: Distribution by Size of Developers
Figure 6.5 Subcutaneous Formulation Technologies: Distribution by Geographical Location of Developers
Figure 6.6 Subcutaneous Formulation Technologies: Distribution by Type of Pharmacological Molecule
Figure 6.7 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Figure 6.8 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Figure 6.9 Logo Landscape: Distribution by Primary Advantage(s) Offered and Company Size of Developer
Figure 7.1 Company Competitiveness Analysis: Four-Dimensional Bubble Chart based on Supplier Power, Pipeline Strength, Primary Advantage(s) and Geographical Location
Figure 7.2 Benchmark Analysis: Subcutaneous Formulation Technology Developers based in North America
Figure 7.3 Benchmark Analysis: Subcutaneous Formulation Technology Developers based in Europe
Figure 8.1 Adocia: Annual Revenues, 2015-Q1 2020 (EUR Million)
Figure 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio
Figure 8.3 Ajinomoto Bio-Pharma Services: Crystalomics® Technology (Process Steps)
Figure 8.4 Ajinomoto: Annual Revenues, FY1415-FY1819 (JPY Billion)
Figure 8.5 Arecor: Arestat™ Technology (Advantages)
Figure 8.6 Ascendis Pharma: Annual Revenues, 2015-2019 (EUR Million)
Figure 8.7 Avadel Pharmaceuticals: Medusa™ Technology (Process Steps)
Figure 8.8 Avadel Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Figure 8.9 Camurus: FluidCrystal® Injection Depot Technology (Process Steps)
Figure 8.10 Camurus: Annual Revenues, 2013-2019 (SEK Million)
Figure 8.11 DURECT: CLOUD Platform (Manufacturing Process)
Figure 8.12 DURECT: Annual Revenues, 2015-2019 (USD Million)
Figure 8.13 Eagle Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Figure 8.14 Halozyme Therapeutics: Annual Revenues, 2015-2019 (USD Million)
Figure 8.15 MedinCell: BEPO® Technology (Process Steps)
Figure 8.16 Xeris Pharmaceuticals: XeriJect™ Technology (Process Steps)
Figure 8.17 Xeris Pharmaceuticals: XeriSol™ Technology (Process Steps)
Figure 8.18 Xeris Pharmaceuticals: Annual Revenues, 2016 – 2019 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2011-2020 (till March)
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2020 (till March)
Figure 9.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2011-2020 (till March)
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and 2016-2020
Figure 9.5 Most Active Players: Distribution by Number of Partnerships
Figure 9.6 Partnerships and Collaborations: Regional Distribution
Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Different Types of Subcutaneous Drug Delivery Systems
Figure 10.2 Subcutaneous Drug Delivery Systems: Overall Market Landscape by Number of Involved Players
Figure 10.3 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Figure 10.4 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Device
Figure 10.5 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose Administered
Figure 10.6 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Volume / Storage Capacity
Figure 10.7 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
Figure 10.8 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mode of Injection
Figure 10.9 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mechanism of Action
Figure 10.10 Large Volume Wearable Injectors for Non-Insulin Biologics: Most Active Players
Figure 10.11 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Figure 10.12 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
Figure 10.13 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
Figure 10.14 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Figure 10.15 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM System
Figure 10.16 Large Volume Wearable Injectors for Insulin: Most Active Players
Figure 10.17 Large Volume Wearable Injectors for Non-Insulin Biologics: Product Competitiveness Analysis
Figure 10.18 Large Volume Wearable Injectors for Insulin: Product Competitiveness Analysis
Figure 10.19 Autoinjectors: Distribution by Usability
Figure 10.20 Autoinjectors: Distribution by Primary Container
Figure 10.21 Autoinjectors: Distribution by Volume / Storage Capacity
Figure 10.22 Autoinjectors: Distribution by Type of Dose
Figure 10.23 Autoinjectors: Distribution by Actuation Mechanism
Figure 10.24 Autoinjectors: Most Active Players
Figure 10.25 Autoinjectors: Product Competitiveness Analysis
Figure 10.26 Pen Injectors: Distribution by Usability
Figure 10.27 Pen Injectors: Distribution by Volume / Storage Capacity
Figure 10.28 Pen Injectors: Distribution by Type of Dose
Figure 10.29 Pen Injectors: Distribution by Most Active Players
Figure 10.30 Needle Free Injection Systems: Distribution by Stage of Development
Figure 10.31 Needle Free Injection Systems: Distribution by Usability
Figure 10.32 Needle Free Injection Systems: Distribution by Disease Area
Figure 10.33 Needle Free Injection Systems: Distribution by Actuation Mechanism
Figure 10.34 Needle Free Injection Systems: Most Active Players
Figure 10.35 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
Figure 10.36 Product Competitiveness Analysis: Compressed Gas-powered Needle-Free Injection Systems
Figure 10.37 Novel Drug Reconstitution Systems: Distribution by Usability
Figure 10.38 Novel Drug Reconstitution Systems: Distribution by Type of Device
Figure 10.39 Novel Drug Reconstitution Systems: Distribution by Dosage Type
Figure 10.40 Novel Drug Reconstitution Systems: Distribution by Type of Drug Container
Figure 10.41 Novel Drug Reconstitution Systems: Most Active Players
Figure 10.42 Prefilled Syringes: Distribution by Barrel Fabrication Material
Figure 10.43 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 10.44 Prefilled Syringes: Distribution by Type of Needle System
Figure 10.45 Prefilled Syringes: Distribution by Volume / Storage Capacity
Figure 10.46 Prefilled Syringes: Most Active Players
Figure 10.47 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 10.48 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 10.49 Implants: Distribution by Stage of Development
Figure 10.50 Implants: Distribution by Target Therapeutic Area
Figure 10.51 Implants: Distribution by Implant Material
Figure 10.52 Implants: Distribution by Treatment Duration
Figure 10.53 Implants: Distribution by Type of Delivery System
Figure 10.54 Implants: Most Active Players
Figure 11.1 SWOT Analysis: Harvey Ball Analysis
Figure 11.2 Number of Biologics Approved by the FDA, 2011-2019
Figure 12.1 Overall Subcutaneous Biologics Market, 2020-2030 (USD Billion)
Figure 12.2 Subcutaneous Biologics Market: Distribution by Phase of Development, 2020-2030 (USD Billion)
Figure 12.3 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Billion)
Figure 12.4 Subcutaneous Biologics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Billion)
Figure 12.5 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (USD Million)
Figure 12.6 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (Units, Million)
Figure 12.7 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 12.8 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 12.9 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (USD Million)
Figure 12.10 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (Units, Million)
Figure 12.11 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 12.12 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030 (Units, Million)
Figure 12.13 Global Large Volume Wearable Injectors Market for Insulin , 2020-2030 (USD Million)
Figure 12.14 Global Large Volume Wearable Injectors Market for Insulin , 2020-2030 (Units, Million)
Figure 12.15 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 12.16 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 12.17 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (USD Million)
Figure 12.18 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (Units, Million)
Figure 12.19 Global Autoinjectors Market, 2020-2030 (USD Million)
Figure 12.20 Global Autoinjectors Market, 2020-2030 (Units, Million)
Figure 12.21 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (USD Million)
Figure 12.22 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (Units, Million)
Figure 12.23 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Million)
Figure 12.24 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (Units, Million)
Figure 12.25 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Figure 12.26 Global Prefilled Syringes Market, 2020-2030 (USD Million)
Figure 12.27 Global Prefilled Syringes Market, 2020-2030 (Units, Million)
Figure 12.28 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, 2020-2030 (USD Million)
Figure 12.29 Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030 (USD Million)
Figure 12.30 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030 (USD Million)
Figure 12.31 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 12.32 Global Needle-Free Injection Systems Market, 2020-2030 (USD Million)
Figure 12.33 Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030 (USD Million)
Figure 12.34 Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030 (USD Million)
Figure 12.35 Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 12.36 Novel Drug Reconstitution Systems Market, 2020-2030 (USD Million)
Figure 12.37 Licensing Agreements: Distribution of Financial Components
Figure 12.38 Subcutaneous Formulation Technologies: Information on Licensing Deals
Figure 12.39 Overall Subcutaneous Formulation Technologies Market, 2020-2030 (USD Million)
Figure 12.40 Subcutaneous Formulation Technologies Market by Upfront Payments, 2020-2030 (USD Million)
Figure 12.41 Subcutaneous Formulation Technologies Market by Milestone Payments, 2020-2030 (USD Million)
Figure 14.1 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020, 2025, 2030 (USD Billion)

List Of Tables

Table 3.1 Comparison of Small Molecules and Biologics
Table 3.2 Parenteral Routes of Administration
Table 3.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
Table 3.4 Parenteral Drug Formulations: Key Excipients
Table 4.1 List of Approved Subcutaneous Biologics
Table 4.2 List of Indications under Different Therapeutic Areas
Table 4.3 Approved Subcutaneous Biologics: Information on Targeted Indication and Therapeutic Area
Table 4.4 Approved Subcutaneous Biologics: Information on Dosing Frequency and Dosage Form
Table 4.5 Approved Subcutaneous Biologics: Distribution by Dosage Form and Therapeutic Area
Table 4.6 List of Clinical-Stage Subcutaneous Biologics
Table 4.7 Clinical-Stage Biologics: Information on Dose, Dosing Frequency and Mechanism of Action
Table 5.1 HUMIRA®: Approved Indications and Dosage Regimen
Table 5.2 Enbrel®: Approved Indications and Dosage Regimen
Table 5.3 RITUXAN® / MabThera®: Approved Indications and Therapy Type
Table 5.4 Comparison of Subcutaneous and Intravenous Formulations of RITUXAN® / MabThera®
Table 5.5 Herceptin®: Approved Indications and Therapy Type
Table 5.6 Comparison of Subcutaneous and Intravenous Formulations of Herceptin®
Table 5.7 Cost Comparison for Patients Treated with Intravenous Herceptin® and Subcutaneous Herceptin®
Table 5.8 Subcutaneous Herceptin® in Single-Use Injection Device: List of Clinical Trials
Table 6.1 List of Subcutaneous Formulation Technologies
Table 6.2 Subcutaneous Formulation Technologies: Information on Type of Pharmacological Molecule
Table 6.3 Subcutaneous Formulation Technologies: Information on Route of Administration
Table 6.4 Subcutaneous Formulations Technologies: Information on Advantage(s) Offered
Table 7.1 Subcutaneous Formulation Technology Developers: Relative Scoring by Supplier Power, Pipeline Strength and Advantage(s) Offered
Table 8.1 Adocia: Product Portfolio
Table 8.2 Adocia: Recent Developments and Future Outlook
Table 8.3 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 8.4 Arecor: Product Portfolio
Table 8.5 Arecor: Recent Developments and Future Outlook
Table 8.6 Alteogen: Product Portfolio
Table 8.7 Alteogen: Recent Developments and Future Outlook
Table 8.8 Ascendis Pharma: Product Portfolio
Table 8.9 Ascendis Pharma: Recent Developments and Future Outlook
Table 8.10 Avadel Pharmaceuticals: Product Portfolio
Table 8.11 Avadel Pharmaceuticals: Recent Developments and Future Outlook
Table 8.12 Camurus: Product Portfolio
Table 8.13 Camurus: Recent Developments and Future Outlook
Table 8.14 DURECT: Product Portfolio
Table 8.15 DURECT: Recent Developments and Future Outlook
Table 8.16 Halozyme Therapeutics: Product Portfolio
Table 8.17 Halozyme Therapeutics: Recent Developments and Future Outlook
Table 8.18 MedinCell: Product Portfolio
Table 8.19 MedinCell: Recent Developments and Future Outlook
Table 8.20 Xeris Pharmaceuticals: Product Portfolio
Table 8.21 Xeris Pharmaceuticals: Recent Developments and Future Outlook
Table 8.22 Serina Therapeutics: Product Portfolio
Table 8.23 Serina Therapeutics: Recent Developments and Future Outlook
Table 9.1 Subcutaneous Formulation Technologies: List of Partnerships and Collaborations, 2011-2020 (till March)
Table 10.1 Subcutaneous Drug Delivery Systems: List of Key Players
Table 10.2 Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
Table 10.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 10.4 Large Volume Wearable Injectors: Development Landscape for Insulin
Table 10.5 Large Volume Drug Device Combinations: Information on Development Status and Device Features
Table 10.6 Autoinjectors: Development Landscape
Table 10.7 List of Drug and Autoinjector Combination Products
Table 10.8 Pen Injectors: Development Landscape
Table 10.9 List of Smart Pen Injectors
Table 10.10 List of Drug and Pen Injector Combination Products
Table 10.11 Needle Free Injection Systems: Development Landscape
Table 10.12 Novel Drug Reconstitution Systems: Development Landscape
Table 10.13 Prefilled Syringe Systems: List of Available / Under Development Devices
Table 10.14 Drugs Approved in Prefilled Syringes, 2013-2019
Table 10.15 Other Drugs Sold in Prefilled Syringes
Table 10.16 Implants: Development Landscape
Table 10.17 Implants: Implants: Information on Material Type, Treatment Duration and Type of Delivery System
Table 10.18 Implants: Subcutaneous Implants Eluting Small Molecules
Table 12.1 Non-Insulin Drug Device Combination Products (Approved / Under Development)
Table 12.2 Therapeutic Areas: Relative Share of Approved and Clinical Products with Prefilled Syringes
Table 12.3 Technology Licensing Deal: Tranches of Milestone Payments
Table 15.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Table 15.2 Approved Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
Table 15.3 Approved Subcutaneous Biologics: Distribution by Target Therapeutic Area
Table 15.4 Approved Subcutaneous Biologics: Distribution by Formulation
Table 15.5 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Table 15.6 Approved Subcutaneous Biologics: Distribution by Dosage Forms
Table 15.7 Key Players: Distribution by Number of Drugs Approved
Table 15.8 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Table 15.9 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Pharmacological Molecule
Table 15.10 Clinical-Stage Subcutaneous Biologics: Distribution by Target Therapeutic Area
Table 15.11 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Table 15.12 Clinical-Stage Subcutaneous Biologics: Key Players
Table 15.13 Subcutaneous Biologics: Leading Drugs by Annual Sales, 2019 (USD Billion)
Table 15.14 HUMIRA®: Annual Sales, 2003-Q1 2020 (USD Billion)
Table 15.15 Enbrel®: Annual Sales in the US and Canada, 2002-Q1 2020 (USD Billion)
Table 15.16 Enbrel®: Annual Sales Outside US and Canada, 2010-Q1 2020 (USD Billion)
Table 15.17 RITUXAN® / MabThera®: Annual Sales, 1999-Q1 2020 (CHF Billion)
Table 15.18 Herceptin®: Annual Sales, 1999-Q1 2020 (CHF Billion)
Table 15.19 Neulasta®: Annual Sales, 2005-2019 (USD Billion)
Table 15.20 Subcutaneous Formulation Technologies: Distribution by Year of Establishment Developers
Table 15.21 Subcutaneous Formulation Technologies: Distribution by Size of Developers
Table 15.22 Subcutaneous Formulation Technologies: Distribution by Geographical Location of Developers
Table 15.23 Subcutaneous Formulation Technologies: Distribution by Type of Pharmacological Molecule
Table 15.24 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Table 15.25 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Table 15.26 Adocia: Annual Revenues, 2015-Q1 2020 (EUR Million)
Table 15.27 Ajinomoto: Annual Revenues, FY1415-FY1819 (JPY Billion)
Table 15.28 Ascendis Pharma: Annual Revenues, 2015-2019 (EUR Million)
Table 15.29 Avadel Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Table 15.30 Camurus: Annual Revenues, 2013-2019 (SEK Million)
Table 15.31 DURECT: Annual Revenues, 2015-2019 (USD Million)
Table 15.32 Eagle Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Table 15.33 Halozyme Therapeutics: Annual Revenues, 2015-2019 (USD Million)
Table 15.34 Xeris Pharmaceuticals: Annual Revenues, 2016 – 2019 (USD Million)
Table 15.35 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2011-2020 (till March)
Table 15.36 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2020 (till March)
Table 15.37 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2011-2020 (till March)
Table 15.38 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and 2016-2020
Table 15.39 Most Active Players: Distribution by Number of Partnerships
Table 15.40 Partnerships and Collaborations: Regional Distribution
Table 15.41 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.42 Subcutaneous Drug Delivery Systems: Overall Market Landscape by Number of Involved Players
Table 15.43 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
Table 15.44 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Device
Table 15.45 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose Administered
Table 15.46 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Volume / Storage Capacity
Table 15.47 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability
Table 15.48 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mode of Injection
Table 15.49 Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Mechanism of Action
Table 15.50 Large Volume Wearable Injectors for Non-Insulin Biologics: Most Active Players
Table 15.51 Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
Table 15.52 Large Volume Wearable Injectors for Insulin: Distribution by Type of Device
Table 15.53 Large Volume Wearable Injectors for Insulin: Distribution by Volume / Storage Capacity
Table 15.54 Large Volume Wearable Injectors for Insulin: Distribution by Usability
Table 15.55 Large Volume Wearable Injectors for Insulin: Distribution by Availability of Integrated CGM / BGM System
Table 15.56 Large Volume Wearable Injectors for Insulin: Most Active Players
Table 15.57 Autoinjectors: Distribution by Usability
Table 15.58 Autoinjectors: Distribution by Primary Container
Table 15.59 Autoinjectors: Distribution by Type of Dose
Table 15.60 Autoinjectors: Distribution by Actuation Mechanism
Table 15.61 Autoinjectors: Most Active Players
Table 15.62 Pen Injectors: Distribution by Usability
Table 15.63 Pen Injectors: Distribution by Volume / Storage Capcity
Table 15.64 Pen Injectors: Distribution by Type of Dose
Table 15.65 Pen Injectors: Most Active Players
Table 15.66 Needle Free Injection Systems: Distribution by Stage of Development
Table 15.67 Needle Free Injection Systems: Distribution by Usability
Table 15.68 Needle Free Injection Systems: Distribution by Disease Area
Table 15.69 Needle Free Injection Systems: Distribution by Actuation Mechanism
Table 15.70 Needle Free Injection Systems: Most Active Players
Table 15.71 Novel Drug Reconstitution Systems: Distribution by Usability
Table 15.72 Novel Drug Reconstitution Systems: Distribution by Type of Device
Table 15.73 Novel Drug Reconstitution Systems: Distribution by Dosage Type
Table 15.74 Novel Drug Reconstitution Systems: Distribution by Type of Drug Container
Table 15.75 Novel Drug Reconstitution Systems: Most Active Players
Table 15.76 Prefilled Syringes: Distribution by Barrel Fabrication Material
Table 15.77 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 15.78 Prefilled Syringes: Distribution by Type of Needle System
Table 15.79 Prefilled Syringes: Distribution by Volume / Storage Capacity
Table 15.80 Prefilled Syringes: Most Active Players
Table 15.81 Implants: Distribution by Stage of Development
Table 15.82 Implants: Distribution by Target Therapeutic Area
Table 15.83 Implants: Distribution by Implant Material
Table 15.84 Implants: Distribution by Treatment Duration
Table 15.85 Implants: Distribution by Type of Delivery System
Table 15.86 Implants: Distribution by Most Active Players
Table 15.87 Number of Biologics Approved by the FDA, 2011-2019
Table 15.88 Subcutaneous Biologics Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.89 Subcutaneous Biologics Market: Distribution by Phase of Development, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.90 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.91 Subcutaneous Biologics Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.92 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.93 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.94 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.95 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.96 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.97 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.98 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.99 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.100 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.101 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.102 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.103 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.104 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.105 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.106 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.107 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.108 Global Autoinjectors Market: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.109 Global Autoinjectors Market: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.110 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.111 Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.112 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.113 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Units, Million)
Table 15.114 Global Prefilled Syringes Market: Distribution by Syringe Barrel Material, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.115 Global Prefilled Syringes Market: Distribution by Type of Chamber System, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.116 Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.117 Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.118 Global Needle-Free Injection Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.119 Global Needle-Free Injection Systems Market: Distribution by Product Usability, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.120 Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.121 Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.122 Novel Drug Reconstitution Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.123 Overall Subcutaneous Formulation Technologies Market, 2020-2030 (USD Million)
Table 15.124 Subcutaneous Formulation Technologies Market by Upfront Payments, 2020-2030 (USD Million)
Table 15.125 Subcutaneous Formulation Technologies Market by Milestone Payments, 2020-2030 (USD Million)
Table 15.126 Subcutaneous Biologics Market: Distribution by Type of Pharmacological Molecule, 2020, 2025, 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3D Medicines
  2. AB2 Bio
  3. Abbott Laboratories
  4. AbbVie
  5. Ablynx
  6. AC Immune
  7. Acceleron Pharma
  8. Accord Healthcare
  9. Acer Therapeutics
  10. ACG Management
  11. Activa Brand Products
  12. Adisave
  13. Adocia
  14. Affibody
  15. Affinivax
  16. Aguettant
  17. Aijex Pharma International
  18. Ajinomoto Bio-Pharma Services
  19. Akcea Therapeutics
  20. Akeso Tiancheng
  21. AKRA DERMOJET
  22. AktiVax
  23. Alder BioPharmaceuticals
  24. Alexion
  25. Alkermes
  26. Allergan
  27. Alnylam Pharmaceuticals
  28. Alopexx Oncology
  29. Alphamab
  30. Alteogen
  31. Altor BioScience
  32. ALTuCELL 
  33. Altus Pharmaceuticals
  34. Alvogen
  35. ALZA 
  36. AMAG Pharmaceuticals
  37. Amedra Pharmaceuticals 
  38. Amgen
  39. Amgen Astellas BioPharma
  40. AnaptysBio
  41. Androsystems
  42. Antares Pharma
  43. Anterogen
  44. Anthera Pharmaceuticals
  45. Aphios
  46. Apobiologix 
  47. Apotex
  48. Araclon Biotech
  49. Arecor
  50. argenx
  51. ARMO BioSciences
  52. Arsia Therapeutics
  53. ARTE 
  54. Asahi Kasei
  55. Ascendis Pharma
  56. ASIT Biotech
  57. ASLAN Pharmaceuticals
  58. Aspen Pharmacare
  59. Astellas Pharma
  60. AstraZeneca
  61. Athyrium Capital Management
  62. Atridia
  63. Avadel Pharmaceuticals
  64. Avant Medical Corporation
  65. Avid Bioservices
  66. Avillion
  67. Axxia Pharmaceuticals
  68. BASF 
  69. Bavarian Nordic
  70. Baxalta
  71. Bay City Capital
  72. Bayer
  73. Becton Dickinson
  74. Beijing Dongfang Biotech
  75. Beijing Northland Biotech
  76. Bespak
  77. Beta-Cell
  78. Beta-O2 Technologies 
  79. Bill & Melinda Gates Foundation
  80. Bioam Gestion
  81. BioAtla
  82. BIOCAD
  83. Biocorp
  84. Biogen
  85. Bioject Medical Technologies
  86. BioMarin Pharmaceutical
  87. Biomay
  88. BioValve
  89. Bird Rock Bio
  90. Boehringer Ingelheim
  91. Boston Pharmaceuticals
  92. Braeburn Pharmaceuticals
  93. Bristol-Myers Squibb
  94. Britannia Pharmaceuticals
  95. Broadfin Capital
  96. Cadila Pharmaceuticals
  97. Calibr
  98. Cam Med
  99. Cambridge Antibody Technology
  100. Cambridge Consultants
  101. Camurus
  102. Carbion
  103. Catalyst Biosciences
  104. CDC Enterprises
  105. Celgene
  106. Celldex Therapeutics
  107. Cellnovo
  108. Central Texas Angel Network 
  109. CeQur
  110. Chondrial Therapeutics
  111. Chugai Pharmaceutical
  112. CinnaGen
  113. Cleveland BioLabs
  114. CM-CIC Innovation
  115. College Diabetes Network
  116. Companion Medical
  117. Complex Biosystems
  118. Copernicus
  119. Corbion
  120. Corvidia Therapeutics
  121. Creative Biolabs
  122. Creative BioMart
  123. Crescendo Pharmaceuticals
  124. Crossject
  125. CSL Behring
  126. CSPC Pharmaceutical 
  127. C-Tri
  128. Cumberland Pharmaceuticals
  129. CuraVac
  130. CytoDyn
  131. Cytori Therapeutics
  132. Daiichi Sankyo
  133. Daikyo Seiko
  134. DALI Medical Devices
  135. D'Antonio Consultants International
  136. Debiotech
  137. Deerfield Management
  138. Delpor
  139. DelSiTech
  140. Dermira
  141. Desentum
  142. DiaMedica Therapeutics
  143. Diamesco
  144. Diasome Pharmaceuticals
  145. Digital Medics
  146. Digna Biotech
  147. Dongbao
  148. Dr. Reddy's Laboratories
  149. DSM Venturing
  150. Duoject Medical Systems
  151. DURECT
  152. Dyax (acquired by Shire)
  153. Eagle Pharmaceuticals
  154. Eddingpharm
  155. Eiger BioPharmaceuticals
  156. Eisai
  157. Elcam Medical
  158. Elektrofi
  159. Eli Lilly
  160. EMD Serono
  161. Emergent BioSolutions
  162. Emperra
  163. Enable Injections
  164. Endo Pharmaceuticals
  165. Enesi Pharma
  166. EOC Pharma
  167. Epilepsy Foundation
  168. Etubics 
  169. European Pharma Group
  170. Ever Supreme Bio Technology
  171. Excelse Bio
  172. EyeTech
  173. Felton International
  174. Ferring Pharmaceuticals
  175. Finox Biotech
  176. Flamel Technologies
  177. Flowonix Medical
  178. FluGen
  179. Fresenius Kabi
  180. FUJIFILM Diosynth Biotechnologies
  181. Future Injection Technologies
  182. Fuze
  183. GALVmed
  184. GC Pharma
  185. Genentech
  186. Generon
  187. Genexine
  188. Genmab
  189. Genor Biopharma
  190. GEROPHARM
  191. Gerresheimer
  192. Gilde Healthcare 
  193. Gilead Sciences
  194. GlaxoSmithKline
  195. Globe Medical Tech
  196. GlobeImmune
  197. Grifols
  198. HAL Allergy
  199. Halozyme Therapeutics
  200. Hanall Biopharma
  201. Hanmi Pharmaceutical
  202. Harbour BioMed
  203. Haselmeier
  204. Health Decisions
  205. Hercules Capital
  206. Heron Therapeutics
  207. Hikma Pharmaceuticals
  208. Hospira
  209. Human Genome Sciences
  210. IDINVEST Partners
  211. ILTOO Pharma
  212. Il-Yang Pharmaceutical
  213. Immunex
  214. Immunomedics
  215. ImmunoVaccine Technologies
  216. ImmusanT
  217. Immutep
  218. Impax Laboratories
  219. Incepta Pharmaceuticals
  220. Indivior
  221. Injecto
  222. INJEX Pharma
  223. Inmunotek
  224. InnoCore Pharmaceuticals
  225. Innovare R&D
  226. Innovate UK
  227. Innovent Biologics
  228. Inolife Sciences
  229. Inovio Pharmaceuticals
  230. i-novion
  231. Insense
  232. Insulet 
  233. Insuline Medical
  234. Intarcia Therapeutics
  235. Integrity Bio
  236. Intrexon
  237. Ipsen
  238. ISU Abxis
  239. Izana Bioscience
  240. Janssen
  241. Janus Capital
  242. JCR Pharmaceuticals
  243. JDRF
  244. Jiangsu Delfu Medical Device
  245. Jiangsu Hengrui Medicine
  246. Jiangsu Wan Hai Medical Instruments
  247. JO Pharma 
  248. Johnson & Johnson
  249. Juvenile Diabetes Research Foundation
  250. Kaléo 
  251. Kangstem Biotech
  252. Kastle Therapeutics
  253. KBI Biopharma
  254. Kedrion Biopharma
  255. King Pharmaceuticals
  256. Kingsbury Capital Partners
  257. Kitasato Daiichi Sankyo Vaccine
  258. Knight Therapeutics
  259. Kolltan Pharmaceuticals
  260. Kyowa Hakko Kirin
  261. Kyowa Kirin 
  262. Laboratorios Liomont
  263. Lapeyronie Hospital
  264. Lenis Medical
  265. LEO Pharma
  266. Leukocare Biotechnology
  267. Lindy Biosciences
  268. Lineage Therapeutics
  269. Lundbeck
  270. Lupin
  271. Luye Pharma
  272. Manchester Institute of Biotechnology
  273. Maruho
  274. Maruishi Pharmaceutical
  275. Massachusetts Institute of Technology
  276. MaxiVAX
  277. McNair Group
  278. Medac Pharma
  279. Medical International Technology
  280. Medicalchain
  281. Medicom Innovation Partner
  282. MedImmune
  283. MedinCell
  284. Medipacs
  285. MedPro 
  286. Medtronic
  287. Medtrum
  288. Merck
  289. Merieux Développement
  290. MGlas 
  291. MicroVAX
  292. Mika Medical
  293. MilliporeSigma
  294. Miracle Medical
  295. Mitsubishi Gas Chemical
  296. Mitsubishi Tanabe Pharma
  297. MJ Biopharm
  298. Momenta Pharmaceuticals
  299. Morphogenesis
  300. MorphoSys
  301. Mylan
  302. Nano Precision Medical
  303. NantCell
  304. National Cancer Institute
  305. National Institute of Allergy and Infectious Diseases
  306. National Institute of Diabetes and Digestive and Kidney Diseases 
  307. National Institute of Neurological Disorders and Stroke
  308. The National Medical Products Administration
  309. Nektar Therapeutics
  310. Nemera
  311. Neumedicines
  312. Neurimmune
  313. NeuroDerm
  314. NGM Biopharmaceuticals
  315. Ningbo Zhengli Pharmaceutical Packing
  316. Nippon Organon
  317. Nipro Medical 
  318. Nordic Group
  319. Novartis
  320. Novimmune
  321. Novo Nordisk
  322. NPS Pharmaceuticals
  323. Nuance Designs 
  324. Numab
  325. Nuova Ompi
  326. OBI Pharma
  327. Omeros 
  328. Ompi
  329. Oncolix
  330. OPKO Health
  331. OrbiMed
  332. Orphan Technologies
  333. Otsuka Pharmaceutical
  334. Oval Medical Technologies
  335. Owen Mumford
  336. Oxford Finance 
  337. PA Consulting 
  338. Pacira BioSciences
  339. Palmetto Partners
  340. PaxVax
  341. Pendiq
  342. Penjet
  343. Pfizer
  344. PharmaJet
  345. Pharmakon Advisors
  346. PharmaSens
  347. Pharmstandard
  348. PhaseBio Pharmaceuticals
  349. PHC Injection Device Technologies
  350. Philogen
  351. Phoundry Pharmaceuticals
  352. Plas-Tech Engineering
  353. Polfa Tarchomin
  354. Population Council
  355. Portal Instruments
  356. Primequal
  357. ProJect Pharmaceutics
  358. Prolynx
  359. Promius Pharma
  360. ProteoThera
  361. Provenance Biopharmaceuticals
  362. Pulse NeedleFree Systems
  363. QS Medical Technology
  364. Qu Biologics
  365. RA Capital Management
  366. Receptos
  367. Recon Therapeutics
  368. Redmile Group
  369. ReForm Biologics
  370. Regeneron Pharmaceuticals
  371. REMD Biotherapeutics
  372. RemeGen
  373. Rentschler Biotechnologie
  374. Revolutions Medical
  375. Rhône-Poulenc Rorer
  376. RMS Medical Products
  377. Roche
  378. Rock Springs Capital
  379. Roselabs Bioscience
  380. ROXALL Medizin
  381. R-Pharm
  382. Sabby Management
  383. Salix Pharmaceuticals
  384. Samsung Bioepis
  385. Sandoz
  386. Sanofi
  387. Santen Pharmaceutical 
  388. Schering-Plough 
  389. Schott
  390. Scripps Research Institute
  391. Sensile Medical
  392. Seqirus
  393. Serina Therapeutics
  394. Sernova
  395. Serum Institute of India
  396. Sewa Medicals
  397. Shandong Pharmaceutical Glass
  398. Shandong Weigao
  399. Shandong Zibo Minkang Pharmaceutical Packing
  400. Shanghai Dahua Pharmaceutical
  401. Shanghai JMT-Bio
  402. Shanghai Junshi Biosciences
  403. Shanghai Umitai Medical Technology 
  404. Shenzhen Salubris Pharmaceuticals
  405. Shin Yan Sheno Precision Industrial
  406. Shire
  407. SHL Medical
  408. Shreya Life Sciences
  409. Silicon Valley Bank
  410. Sinocelltech
  411. SiO2 Medical Products
  412. SK Chemicals
  413. Société Générale Asset Management
  414. Sofinnova Partners
  415. Solteam Medical
  416. SOOIL Development
  417. SOTIO
  418. Spectrum Pharmaceuticals
  419. Square Pharmaceuticals
  420. STADA Arzneimittel
  421. SteadyMed Therapeutics
  422. Stemirna Therapeutics
  423. Subcuject
  424. Sumitomo Dainippon Pharma
  425. Sun Pharmaceutical Industries
  426. Swedish Orphan Biovitrum
  427. Synermore Biologics
  428. Synthon Hispania
  429. Taisei Kako
  430. Taisho Pharmaceutical
  431. Takeda Pharmaceutical
  432. Talecris Biotherapeutics
  433. Tandem Diabetes Care
  434. Technical University of Munich
  435. Telegraph Hill Partners
  436. TerSera Therapeutics
  437. Terumo
  438. Teva Pharmaceuticals
  439. Texan Allergy & Sinus Center
  440. Texas Diabetes Institute
  441. Texas Emerging Technologies Fund
  442. The National Institute for Health and Care Excellence
  443. The National Medical Products
  444. The Wyss Institute at Harvard University
  445. TheraCyte
  446. Theralpha
  447. Tianjin SinoBiotech
  448. Titan Pharmaceuticals
  449. Tonghua Dongbao
  450. Torii Pharmaceutical
  451. Touche Medical
  452. Transcoject
  453. Transgene
  454. TREOS Bio
  455. Tyfill Pharmapack
  456. U.S. Medical Instruments
  457. UCB Pharma
  458. Ultragenyx Pharmaceutical
  459. Uman Pharma
  460. Uni-Bio Science Group
  461. Unilever
  462. Unilife 
  463. Union Medico
  464. United BioPharma
  465. United Therapeutics
  466. University of Colorado
  467. University of Texas Health Science Center
  468. US WorldMeds
  469. Valeant Pharmaceuticals 
  470. Valeritas
  471. Venrock
  472. Ventana Medical Systems
  473. Vetter Pharma
  474. ViaCyte
  475. ViCentra
  476. Viela Bio
  477. ViiV Healthcare
  478. ViroMed
  479. ViroPharma
  480. Vitaeris
  481. Vivo Capital
  482. Wanhai Medical
  483. West Pharmaceutical Services
  484. Wild Basin Investments
  485. XBiotech
  486. Xellia Pharmaceuticals
  487. XEME Biopharma
  488. Xencor
  489. Xeris Pharmaceuticals
  490. YangZhong Wealth Metal
  491. Youlyy Industrial
  492. Ypsomed
  493. Zensun
  494. Zogenix
  495. Zweite TechnoStart Ventures Fonds

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com